The sale is small relative to market cap and the insider's role is a business unit president, not the CEO/CFO. The prior tax-motivated sale pattern suggests this may be routine. Monitor for the actual sale on Form 4 and any subsequent insider selling patterns.
TAK drugs
TAK drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 2 $20.87entry
- T+1 · 14d ago −0.57%α −0.87% · $20.75
- T+5 · 8d ago +1.05%α +0.98% · $21.09
- T+10 · todayOpen
- T+20 · in 14d Pending
- T+60 · in 2mo Pending
Price Chart
How similar events traded
Executive Summary
Teresa Bitetti, President of Takeda's Global Oncology Business Unit, filed a Form 144 to sell 46,609 American Depositary Shares (ADSs) with an approximate market value of $940,104. The sale is scheduled for or after November 1, 2026. The filing notes that a prior sale in August 2026 was to satisfy tax obligations related to share vesting, suggesting this proposed sale may also be for tax or routine portfolio management purposes.
Key Facts
- Insider: Teresa Bitetti, President, Global Oncology Business Unit
- Proposed sale of 46,609 ADSs, approximate value $940,104
- Proposed sale date: on or after November 1, 2026
- Prior sale of 50,012 ADSs on August 10, 2026 was to satisfy tax obligations from share vesting
- Shares were acquired via vested Restricted Stock Unit Awards on July 30, 2024
- Market cap of Takeda: $63.7 billion; sale represents ~0.0015% of market cap
Financial Impact
Proposed sale of $940,104 in ADSs, representing a negligible fraction of the company's $63.7B market cap.
Risk Factors
- Form 144 signals intent to sell; the sale may not be completed.
- If this sale is followed by larger insider sales or by other executives, it could indicate broader insider sentiment.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001493152-26-049485 |
| Document: 0001493152-26-049485-index.html | 0001493152-26-049485 |
| Document: 0001493152-26-049485.txt | 0001493152-26-049485 |
Track record
18 reports on TAK
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $21.19 to $21.12 Now $21.59 +1.89% ▼ −0.33% −3.62% vs SPY
- Oct 30, 202617d ago 144 Neutral 2/10 Entry $20.87 to $21.09 Now $21.59 +3.45% ▲ +1.05% +0.98% vs SPY
- Oct 30, 202617d ago 144 Neutral 2/10 Viewing Entry $20.87 to $21.09 Now $21.59 +3.45% ▲ +1.05% +0.98% vs SPY
- Oct 29, 202618d ago 6-K Neutral 4/10 No price data
- Oct 29, 202618d ago 6-K Bearish 5/10 Entry $20.01 to $21.19 Now $21.59 −7.90% ▼ −5.90% −10.62% vs SPY
- Sep 14, 20269w ago 6-K Bullish 7/10 Entry $18.60 to $18.89 Now $21.59 +16.08% ▲ +1.56% +1.45% vs SPY
- Aug 21, 202612w ago Insider Cluster Neutral 2/10 Entry $18.24 to $17.98 Now $21.59 +18.37% ▼ −1.43% −1.89% vs SPY
- Aug 19, 202612w ago Insider Cluster Neutral 2/10 Entry $18.13 to $18.03 Now $21.59 +19.08% ▼ −0.55% −1.67% vs SPY
- Aug 14, 202613w ago Court Ruling Neutral 4/10 Entry $17.38 to $18.24 Now $21.59 +24.22% ▲ +4.95% +6.14% vs SPY
- Aug 12, 202613w ago Insider Cluster Neutral 3/10 Entry $17.39 to $18.13 Now $21.59 +24.15% ▲ +4.26% +6.22% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers